Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Major house dust mite allergens are a group of proteins derived primarily from *Dermatophagoides pteronyssinus* that are recognized by the immune system of allergic patients, with Der p 1 (cysteine protease), Der p 2 (lipid-binding protein homologous to NPC2 and MD-2), and Der p 23 (peritrophin-like chitin-binding protein) being the most clinically important[1][5][3]. These allergens are responsible for the majority of IgE reactivity in house dust mite-allergic individuals and are major triggers for asthma, rhinitis, and atopic eczema. They are used as major molecular components in allergy diagnostics and specific immunotherapy, and they interact directly and indirectly with immune pathways, including protease activity (Der p 1), lipid/cholesterol binding (Der p 2), and innate immune recognition.
Induction of IgE-mediated hypersensitivity; Activation of basophils and mast cells; Upregulation of immune activation markers (e.g., CD203c by Der p 23); Some (e.g., Der p 2) can mimic or activate TLR4 pathways
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Major house dust mite allergen (Der p 1, Der p 2, Der p 23) (Der p 1, Der p 2, Der p 23).